Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model

Simmerman, Erika; Xu, Qin; Yu, Jack C.; Baban, Babak

doi:10.1016/j.jss.2018.08.055

Cited by 65 publications

(54 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two of the selected studies clearly demonstrated this; the use of THC in mice with induced BRAF/NRAS wild-type tumors promoted autophagy in melanoma cells [32]. Similarly, the use of CBD on mice with an induced B16F110 tumor significantly reduced tumorigenicity and tumor size [31].…”

Section: Discussionmentioning

confidence: 94%

“…Marijuana is classified as an illicit drug and its use is prohibited in most countries. However, cannabis/hemp strains contain over 120 phytocannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), which are thought to be of therapeutic more importance [22,31,43]. Apart from phytocannabinoids, other classes of cannabinoids such as endocannabinoids and chemically synthetic cannabinoids are known [44].…”

Section: Discussionmentioning

confidence: 99%

“…This is its main benefit compared to chemotherapeutic agents which also affect cancerous tissues [30]. Extracts from Cannabis sativa L. have the potential not only to enhance survival rates but also to potentially improve the quality of life in melanoma patients [31]. While a great number of in vitro studies [32] (see Glodde et al (2015)) have provided evidence of positive outcomes on using cannabinoids for treating melanoma cells, there are few in vivo and clinical studies that have been published [33,34].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies

Bachari

Piva

Salami

et al. 2020

IJMS

View full text Add to dashboard Cite

Melanoma is the fourth most common type of cancer diagnosed in Australians after breast, prostate, and colorectal cancers. While there has been substantial progress in the treatment of cancer in general, malignant melanoma, in particular, is resistant to existing medical therapies requiring an urgent need to develop effective treatments with lesser side effects. Several studies have shown that “cannabinoids”, the major compounds of the Cannabis sativaL. plant, can reduce cell proliferation and induce apoptosis in melanoma cells. Despite prohibited use of Cannabis in most parts of the world, in recent years there have been renewed interests in exploiting the beneficial health effects of the Cannabis plant-derived compounds. Therefore, the aim of this study was in the first instance to review the evidence from in vivo studies on the effects of cannabinoids on melanoma. Systematic searches were carried out in PubMed, Embase, Scopus, and ProQuest Central databases for relevant articles published from inception. From a total of 622 potential studies, six in vivo studies assessing the use of cannabinoids for treatment of melanoma were deemed eligible for the final analysis. The findings revealed cannabinoids, individually or combined, reduced tumor growth and promoted apoptosis and autophagy in melanoma cells. Further preclinical and animal studies are required to determine the underlying mechanisms of cannabinoids-mediated inhibition of cancer-signaling pathways. Well-structured, randomized clinical studies on cannabinoid use in melanoma patients would also be required prior to cannabinoids becoming a viable and recognized therapeutic option for melanoma treatment in patients.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies

Bachari

Piva

Salami

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…This could be attributed to a relatively higher incidence of BCC, in the Middle East populations than westerns . Western reports have higher incidence of melanoma, which has a worse potentiality outcome . This study is describing only the surgical outcomes of cutaneous cancer in the face, without use of any adjuvant therapy like chemical or radiation therapies, as in the study carried out by Mendez and Thornton in 2017 …”

Section: Discussionmentioning

confidence: 95%

Facial skin cancer reconstructive and cosmetic outcomes: Analysis with algorithm for its management

Ali

Mohamed

Nasef

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background: Management of facial skin cancer and its complications is important research topics needing continuous update to improve the outcome. Objective:The study is to share our findings with surgeons and healthcare providers.The authors provide their efforts by pooling data from multiple institutions; as reporting surgical outcomes is significantly lacking and much needed in the Middle East and North Africa region in order to meaningfully improve quality of care. This study proposes an algorithm for management that could aid a surgical decision-making for reconstruction of defects after excision of facial skin cancer. Methods:Retrograde simple descriptive analysis study is conducted for multicenter data about management of facial skin cancer and its cosmetic outcome. The analysis involves 159 male patients and 95 females.Results: Nonmelanoma skin cancer was reported in 250 (98.4%) of 254 cases.Reconstructive procedures were complicated in 16 cases (~6.3% of the study). Skin cancer recurrence in head and neck has happened in five cases (~1.9% of the study).Flaps used survived without major complications; however, V-Y advancement flaps showed the best aesthetic outcome. Conclusion:This study reports data in order to meaningfully improve the quality of care. Disease incidence, reconstructive complications, recurrences, and aesthetic outcome of facial skin cancer are included in the study. Based on the data pooling, the study proposes a simple treatment algorithm that could aid in surgical decisionmaking. V-Y advancement flaps showed the best aesthetic outcome. K E Y W O R D Saesthetic, algorithm, face, multicenters, skin cancer | INTRODUC TI ONSkin cancer is classified into melanoma and nonmelanoma types. 1,2 Incidence of each type varies according to a genetic, predisposing, 3 ethnic, or geographic factor. 4 In management of facial, scalp, and neck skin cancer, surgery always has a basic contribution. 5 Surgeons and dermatologists have many choices for the closure of the defects after excision, according to each lesion; site and size, patient age skin elasticity, in addition to individual experience and understanding of facial proportion. 6,7

show abstract

“…Other authors suggest that the anti-tumoral effects of CBD may also rely on CB2-mediated anti-inflammatory or immuno-modulating activities [170]. CBD alone was tested for anti-tumoral efficacy in melanoma against Cisplatin when administered intraperitoneally on murine B16F10 melanoma tumors, and even though tumor growth restriction and survival length were better for Cisplatin, the quality of life and movement were better in CBD treated animals [171]. Moreover, the in vivo effects of THC on melanoma have been demonstrated to be CB1 and CB2 mediated.…”

Section: Melanomamentioning

confidence: 99%

Cannabinoids in the Pathophysiology of Skin Inflammation

et al. 2020

View full text Add to dashboard Cite

Cannabinoids are increasingly-used substances in the treatment of chronic pain, some neuropsychiatric disorders and more recently, skin disorders with an inflammatory component. However, various studies cite conflicting results concerning the cellular mechanisms involved, while others suggest that cannabinoids may even exert pro-inflammatory behaviors. This paper aims to detail and clarify the complex workings of cannabinoids in the molecular setting of the main dermatological inflammatory diseases, and their interactions with other substances with emerging applications in the treatment of these conditions. Also, the potential role of cannabinoids as antitumoral drugs is explored in relation to the inflammatory component of skin cancer. In vivo and in vitro studies that employed either phyto-, endo-, or synthetic cannabinoids were considered in this paper. Cannabinoids are regarded with growing interest as eligible drugs in the treatment of skin inflammatory conditions, with potential anticancer effects, and the readiness in monitoring of effects and the facility of topical application may contribute to the growing support of the use of these substances. Despite the promising early results, further controlled human studies are required to establish the definitive role of these products in the pathophysiology of skin inflammation and their usefulness in the clinical setting.

show abstract

Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model

Cited by 65 publications

References 25 publications

Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies

Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies

Facial skin cancer reconstructive and cosmetic outcomes: Analysis with algorithm for its management

Cannabinoids in the Pathophysiology of Skin Inflammation

Contact Info

Product

Resources

About